Treatment and prevention of acute bleedings in von Willebrand disease - Efficacy and safety of Wilate®, a new generation von Willebrand factor/factor VIII concentrate

Haemophilia

Volumn 15, Issue 1, 2009, Pages 122-130

  Berntorp, Erik ^a   Windyga, J ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Bleeding, factor VIII; Prophylaxis; Von Willebrand disease; Von Willebrand factor; Wilate

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WILATE;

ABDOMINAL DISCOMFORT; ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BOLUS INJECTION; CHEMOPROPHYLAXIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LOADING DRUG DOSE; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK REDUCTION; THROMBOSIS; TREATMENT DURATION; URTICARIA; VERTIGO; VON WILLEBRAND DISEASE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FACTOR VIII; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 63049123172     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01901.x     Document Type: Article

References (27)

1. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
2. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-21.
3. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351: 683-94.
4. Mannucci PM. Desmopressin: A nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449-55.
5. Pasi KJ, Williams MD, Enayat MS, Hill FG. Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y). Br J Haematol 1990; 75: 228-33.
6. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992; 65: 253-9.
7. Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickles FR. The use of intermediate and high purity factor VIII products in the treatment of Von Willebrand disease. Thromb Haemost 1994; 71: 173-9.
8. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 4 (Suppl. 3): 33-9.
9. Stadler M, Gruber G, Kannicht C et al. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate). Biologicals 2006; 34: 281-8.
10. Federici AB, Caracciolo C, Mancuso G et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: A retrospective clinical study. Haemophilia 2002; 8: 761-7.
11. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: A cross-over randomized trial. Blood 1992; 79: 3130-7.
12. EMEA Committee for medicinal products for human use (CPMP). Guideline on the clinical investigation of human plasma derived von Willebrand factor products (CPMP/BPWG/220/02). London, UK: European Medicines Agency, November 2005.
13. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/ Humate-P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224-30.
14. Goudemand J, Scharrer I, Berntorp E et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. Thromb Haemost 2005; 3: 2219-27.
15. Menache D, Aronson DL, Darr F et al. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): Estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. Br J Haematol 1996; 94: 740-5.
16. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004; 10: 243-9.
17. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97: 1915-9.
18. Pock K, Stadler M, Gruber G, Kannicht C, Römisch J, Svae TE. Product features of the novel generation VWF/FVIII concentrate in a comparison with first generation products. J Thromb Haemost 2007; 5 (Suppl. 1): P-W-183.
19. Furlan M. Von Willebrand factor: Molecular size and functional activity. Ann Hematol 1996; 72: 341-8.
20. Federici AB, Bader R, Pagani S, Colibretti ML, De Marco L, Mannucci PM. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: Affinity is related to multimeric size. Br J Haematol 1989; 73: 93-9.
21. Mannucci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002; 99: 450-6.
22. Berntorp E. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3. Semin Thromb Hemost 2006; 32: 621-5.
23. Federici AB, Castaman G, Franchini M et al. Clinical use of Haemate ® P in inherited von Willebrand's disease: A cohort study on 100 Italian patients. Haematologica 2007; 92: 944-51.
24. Nowak-Gottl U, Auerswald G, Feddern J et al. Prospective post licensure surveillance of efficacy and tolerability of a high purity, double virus inactivated VWF/FVIII concentrate in the treatment of von Willebrand's disease. J Thromb Haemost 2007; 5 (Suppl. 1): P-W-181.
25. Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P ®). Haemophilia 2004; 10: 42-51.
26. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002; 15: 485-505.
27. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997; 72: 1-10.